Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma

Metastatic pancreatic ductal adenocarcinoma: diagnosis and treatment with a view to the future

(2018) Adrian M. J. Pokorny et al.   INTERNAL MEDICINE JOURNAL

Targeting both tumour-associated CXCR2+neutrophils and CCR2+macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma

(2017) Timothy M Nywening et al.   GUT

Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies

(2017) Aleksandra Adamska et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Gemcitabine-Related Pneumonitis in Pancreas Adenocarcinoma—An Infrequent Event: Elucidation of Risk Factors and Management Implications

(2016) Ibrahim Halil Sahin et al.   Clinical Colorectal Cancer

Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial

(2016) Timothy M Nywening et al.   LANCET ONCOLOGY

Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies

(2015) E. Gabriela Chiorean et al.   Drug Design Development and Therapy

Pancreatic Adenocarcinoma

(2015) David P. Ryan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States

(2014) L. Rahib et al.   CANCER RESEARCH

Breaking immunotolerance of tumors: A new perspective for dendritic cell therapy

(2014) Jacek Rolinski et al.   Journal of Immunotoxicology

Tumor microenvironment profoundly modifies functional status of macrophages: Peritoneal and tumor-associated macrophages are two very different subpopulations

(2013) Dayron Rodríguez et al.   CELLULAR IMMUNOLOGY

Inflammatory Monocyte Mobilization Decreases Patient Survival in Pancreatic Cancer: A Role for Targeting the CCL2/CCR2 Axis

(2013) D. E. Sanford et al.   CLINICAL CANCER RESEARCH

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

(2013) Daniel D. Von Hoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting Tumor-Infiltrating Macrophages Decreases Tumor-Initiating Cells, Relieves Immunosuppression, and Improves Chemotherapeutic Responses

(2012) J. B. Mitchem et al.   CANCER RESEARCH

Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial

(2011) Daniel D. Von Hoff et al.   JOURNAL OF CLINICAL ONCOLOGY

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity

(2010) Suzanne Ostrand-Rosenberg   CANCER IMMUNOLOGY IMMUNOTHERAPY

Pancreatic Cancer

(2010) Manuel Hidalgo   NEW ENGLAND JOURNAL OF MEDICINE

Myeloid-Derived Suppressor Cells Inhibit T-Cell Activation by Depleting Cystine and Cysteine

(2009) M. K. Srivastava et al.   CANCER RESEARCH

Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer

(2009) S. Ostrand-Rosenberg et al.   JOURNAL OF IMMUNOLOGY

Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy

(2008) C. Marcela Diaz-Montero et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

CANCER IMMUNOLOGY: Cancer's Bulwark Against Immune Attack: MDS Cells

(2008) J. Marx   SCIENCE

Mutant MCP-1 therapy inhibits tumor angiogenesis and growth of malignant melanoma in mice

(2007) Mitsuhisa Koga et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS